A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy
Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2023-03, Vol.41 (13), p.2101-2112 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2112 |
|---|---|
| container_issue | 13 |
| container_start_page | 2101 |
| container_title | Vaccine |
| container_volume | 41 |
| creator | Moore, Kristine A. Leighton, Tabitha Ostrowsky, Julia T. Anderson, Cory J. Danila, Richard N. Ulrich, Angela K. Lackritz, Eve M. Mehr, Angela J. Baric, Ralph S. Baylor, Norman W. Gellin, Bruce G. Gordon, Jennifer L. Krammer, Florian Perlman, Stanley Rees, Helen V. Saville, Melanie Weller, Charlotte L. Osterholm, Michael T. |
| description | Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) is aimed at promoting the development of such vaccines. The CVR, funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, was generated through a collaborative and iterative process, which was led by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and involved 50 international subject matter experts and recognized leaders in the field. This report summarizes the major issues and areas of research outlined in the CVR and identifies high-priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 26 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research campaigns that promote the development of broadly protective coronavirus vaccines. |
| doi_str_mv | 10.1016/j.vaccine.2023.02.032 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9941884</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X23001676</els_id><sourcerecordid>2789718511</sourcerecordid><originalsourceid>FETCH-LOGICAL-c528t-496bee6053ebf088ed9e31e2ccc62cd10efff4f21ae0ca6926b89fcf9ca840dd3</originalsourceid><addsrcrecordid>eNqFkl2L1DAUhoso7rj6E5SAIOtFa5KmaeKFMqyfsCCIgnchTU52M7RNN2kL8-_NMOOi3uxVSPKc93y9RfGc4Ipgwt_sqlUb40eoKKZ1hWmFa_qg2BDR1iVtiHhYbDDlrGQE_zornqS0wxg3NZGPi7OaixaLlm2KdYsiJNDR3CA9WmRhhT5MA4wzuvj-6sNrFIO2g56QCxF1h0u_R1MMM5jZr4BMiGHUq49LQqeK0lu0RVNWg8GbzMKkI9j8nlCao57hev-0eOR0n-DZ6Twvfn76-OPyS3n17fPXy-1VaRoq5pJJ3gHwXDZ0DgsBVkJNgBpjODWWYHDOMUeJBmw0l5R3QjrjpNGCYWvr8-LdUXdaugGsyW1F3asp-kHHvQraq39_Rn-jrsOqpGRECJYFLk4CMdwukGY1-GSg7_UIYUmKiprRhnNW34-2mZUsK2f05X_oLixxzJM4ULIloiEkU82RMjGkFMHd1U2wOphA7dRp5OpgAoWpyibIcS_-bvou6s_WM_D-CEAe_eohqmQ8jAasj3mtygZ_T4rf8b3Iyg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2789718511</pqid></control><display><type>article</type><title>A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Moore, Kristine A. ; Leighton, Tabitha ; Ostrowsky, Julia T. ; Anderson, Cory J. ; Danila, Richard N. ; Ulrich, Angela K. ; Lackritz, Eve M. ; Mehr, Angela J. ; Baric, Ralph S. ; Baylor, Norman W. ; Gellin, Bruce G. ; Gordon, Jennifer L. ; Krammer, Florian ; Perlman, Stanley ; Rees, Helen V. ; Saville, Melanie ; Weller, Charlotte L. ; Osterholm, Michael T.</creator><creatorcontrib>Moore, Kristine A. ; Leighton, Tabitha ; Ostrowsky, Julia T. ; Anderson, Cory J. ; Danila, Richard N. ; Ulrich, Angela K. ; Lackritz, Eve M. ; Mehr, Angela J. ; Baric, Ralph S. ; Baylor, Norman W. ; Gellin, Bruce G. ; Gordon, Jennifer L. ; Krammer, Florian ; Perlman, Stanley ; Rees, Helen V. ; Saville, Melanie ; Weller, Charlotte L. ; Osterholm, Michael T. ; The Coronavirus Vaccines R&D Roadmap Taskforce ; Coronavirus Vaccines R&D Roadmap Taskforce</creatorcontrib><description>Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) is aimed at promoting the development of such vaccines. The CVR, funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, was generated through a collaborative and iterative process, which was led by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and involved 50 international subject matter experts and recognized leaders in the field. This report summarizes the major issues and areas of research outlined in the CVR and identifies high-priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 26 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research campaigns that promote the development of broadly protective coronavirus vaccines.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2023.02.032</identifier><identifier>PMID: 36870874</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Animal models ; Animals ; Broadly protective coronavirus vaccines ; Charities ; Coronavirus ; Coronavirus vaccines ; Coronaviruses ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 Vaccines ; Epidemics ; finance ; human diseases ; Humans ; Immunology ; Infectious diseases ; issues and policy ; Iterative methods ; Medical research ; Middle East respiratory syndrome ; Minnesota ; pandemic ; Pandemic preparedness ; Pandemics ; Pandemics - prevention & control ; Product development ; Public health ; R&D ; Research & development ; research and development ; Review ; Roadmap ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; vaccine development ; Vaccine research ; Vaccines ; Viral diseases ; virology</subject><ispartof>Vaccine, 2023-03, Vol.41 (13), p.2101-2112</ispartof><rights>2023 The Author(s)</rights><rights>Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.</rights><rights>2023. The Author(s)</rights><rights>2023 The Author(s) 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c528t-496bee6053ebf088ed9e31e2ccc62cd10efff4f21ae0ca6926b89fcf9ca840dd3</citedby><cites>FETCH-LOGICAL-c528t-496bee6053ebf088ed9e31e2ccc62cd10efff4f21ae0ca6926b89fcf9ca840dd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X23001676$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36870874$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moore, Kristine A.</creatorcontrib><creatorcontrib>Leighton, Tabitha</creatorcontrib><creatorcontrib>Ostrowsky, Julia T.</creatorcontrib><creatorcontrib>Anderson, Cory J.</creatorcontrib><creatorcontrib>Danila, Richard N.</creatorcontrib><creatorcontrib>Ulrich, Angela K.</creatorcontrib><creatorcontrib>Lackritz, Eve M.</creatorcontrib><creatorcontrib>Mehr, Angela J.</creatorcontrib><creatorcontrib>Baric, Ralph S.</creatorcontrib><creatorcontrib>Baylor, Norman W.</creatorcontrib><creatorcontrib>Gellin, Bruce G.</creatorcontrib><creatorcontrib>Gordon, Jennifer L.</creatorcontrib><creatorcontrib>Krammer, Florian</creatorcontrib><creatorcontrib>Perlman, Stanley</creatorcontrib><creatorcontrib>Rees, Helen V.</creatorcontrib><creatorcontrib>Saville, Melanie</creatorcontrib><creatorcontrib>Weller, Charlotte L.</creatorcontrib><creatorcontrib>Osterholm, Michael T.</creatorcontrib><creatorcontrib>The Coronavirus Vaccines R&D Roadmap Taskforce</creatorcontrib><creatorcontrib>Coronavirus Vaccines R&D Roadmap Taskforce</creatorcontrib><title>A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) is aimed at promoting the development of such vaccines. The CVR, funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, was generated through a collaborative and iterative process, which was led by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and involved 50 international subject matter experts and recognized leaders in the field. This report summarizes the major issues and areas of research outlined in the CVR and identifies high-priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 26 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research campaigns that promote the development of broadly protective coronavirus vaccines.</description><subject>Animal models</subject><subject>Animals</subject><subject>Broadly protective coronavirus vaccines</subject><subject>Charities</subject><subject>Coronavirus</subject><subject>Coronavirus vaccines</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>Epidemics</subject><subject>finance</subject><subject>human diseases</subject><subject>Humans</subject><subject>Immunology</subject><subject>Infectious diseases</subject><subject>issues and policy</subject><subject>Iterative methods</subject><subject>Medical research</subject><subject>Middle East respiratory syndrome</subject><subject>Minnesota</subject><subject>pandemic</subject><subject>Pandemic preparedness</subject><subject>Pandemics</subject><subject>Pandemics - prevention & control</subject><subject>Product development</subject><subject>Public health</subject><subject>R&D</subject><subject>Research & development</subject><subject>research and development</subject><subject>Review</subject><subject>Roadmap</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>vaccine development</subject><subject>Vaccine research</subject><subject>Vaccines</subject><subject>Viral diseases</subject><subject>virology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkl2L1DAUhoso7rj6E5SAIOtFa5KmaeKFMqyfsCCIgnchTU52M7RNN2kL8-_NMOOi3uxVSPKc93y9RfGc4Ipgwt_sqlUb40eoKKZ1hWmFa_qg2BDR1iVtiHhYbDDlrGQE_zornqS0wxg3NZGPi7OaixaLlm2KdYsiJNDR3CA9WmRhhT5MA4wzuvj-6sNrFIO2g56QCxF1h0u_R1MMM5jZr4BMiGHUq49LQqeK0lu0RVNWg8GbzMKkI9j8nlCao57hev-0eOR0n-DZ6Twvfn76-OPyS3n17fPXy-1VaRoq5pJJ3gHwXDZ0DgsBVkJNgBpjODWWYHDOMUeJBmw0l5R3QjrjpNGCYWvr8-LdUXdaugGsyW1F3asp-kHHvQraq39_Rn-jrsOqpGRECJYFLk4CMdwukGY1-GSg7_UIYUmKiprRhnNW34-2mZUsK2f05X_oLixxzJM4ULIloiEkU82RMjGkFMHd1U2wOphA7dRp5OpgAoWpyibIcS_-bvou6s_WM_D-CEAe_eohqmQ8jAasj3mtygZ_T4rf8b3Iyg</recordid><startdate>20230324</startdate><enddate>20230324</enddate><creator>Moore, Kristine A.</creator><creator>Leighton, Tabitha</creator><creator>Ostrowsky, Julia T.</creator><creator>Anderson, Cory J.</creator><creator>Danila, Richard N.</creator><creator>Ulrich, Angela K.</creator><creator>Lackritz, Eve M.</creator><creator>Mehr, Angela J.</creator><creator>Baric, Ralph S.</creator><creator>Baylor, Norman W.</creator><creator>Gellin, Bruce G.</creator><creator>Gordon, Jennifer L.</creator><creator>Krammer, Florian</creator><creator>Perlman, Stanley</creator><creator>Rees, Helen V.</creator><creator>Saville, Melanie</creator><creator>Weller, Charlotte L.</creator><creator>Osterholm, Michael T.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><general>The Author(s). Published by Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope></search><sort><creationdate>20230324</creationdate><title>A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy</title><author>Moore, Kristine A. ; Leighton, Tabitha ; Ostrowsky, Julia T. ; Anderson, Cory J. ; Danila, Richard N. ; Ulrich, Angela K. ; Lackritz, Eve M. ; Mehr, Angela J. ; Baric, Ralph S. ; Baylor, Norman W. ; Gellin, Bruce G. ; Gordon, Jennifer L. ; Krammer, Florian ; Perlman, Stanley ; Rees, Helen V. ; Saville, Melanie ; Weller, Charlotte L. ; Osterholm, Michael T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c528t-496bee6053ebf088ed9e31e2ccc62cd10efff4f21ae0ca6926b89fcf9ca840dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Animal models</topic><topic>Animals</topic><topic>Broadly protective coronavirus vaccines</topic><topic>Charities</topic><topic>Coronavirus</topic><topic>Coronavirus vaccines</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>Epidemics</topic><topic>finance</topic><topic>human diseases</topic><topic>Humans</topic><topic>Immunology</topic><topic>Infectious diseases</topic><topic>issues and policy</topic><topic>Iterative methods</topic><topic>Medical research</topic><topic>Middle East respiratory syndrome</topic><topic>Minnesota</topic><topic>pandemic</topic><topic>Pandemic preparedness</topic><topic>Pandemics</topic><topic>Pandemics - prevention & control</topic><topic>Product development</topic><topic>Public health</topic><topic>R&D</topic><topic>Research & development</topic><topic>research and development</topic><topic>Review</topic><topic>Roadmap</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>vaccine development</topic><topic>Vaccine research</topic><topic>Vaccines</topic><topic>Viral diseases</topic><topic>virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moore, Kristine A.</creatorcontrib><creatorcontrib>Leighton, Tabitha</creatorcontrib><creatorcontrib>Ostrowsky, Julia T.</creatorcontrib><creatorcontrib>Anderson, Cory J.</creatorcontrib><creatorcontrib>Danila, Richard N.</creatorcontrib><creatorcontrib>Ulrich, Angela K.</creatorcontrib><creatorcontrib>Lackritz, Eve M.</creatorcontrib><creatorcontrib>Mehr, Angela J.</creatorcontrib><creatorcontrib>Baric, Ralph S.</creatorcontrib><creatorcontrib>Baylor, Norman W.</creatorcontrib><creatorcontrib>Gellin, Bruce G.</creatorcontrib><creatorcontrib>Gordon, Jennifer L.</creatorcontrib><creatorcontrib>Krammer, Florian</creatorcontrib><creatorcontrib>Perlman, Stanley</creatorcontrib><creatorcontrib>Rees, Helen V.</creatorcontrib><creatorcontrib>Saville, Melanie</creatorcontrib><creatorcontrib>Weller, Charlotte L.</creatorcontrib><creatorcontrib>Osterholm, Michael T.</creatorcontrib><creatorcontrib>The Coronavirus Vaccines R&D Roadmap Taskforce</creatorcontrib><creatorcontrib>Coronavirus Vaccines R&D Roadmap Taskforce</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moore, Kristine A.</au><au>Leighton, Tabitha</au><au>Ostrowsky, Julia T.</au><au>Anderson, Cory J.</au><au>Danila, Richard N.</au><au>Ulrich, Angela K.</au><au>Lackritz, Eve M.</au><au>Mehr, Angela J.</au><au>Baric, Ralph S.</au><au>Baylor, Norman W.</au><au>Gellin, Bruce G.</au><au>Gordon, Jennifer L.</au><au>Krammer, Florian</au><au>Perlman, Stanley</au><au>Rees, Helen V.</au><au>Saville, Melanie</au><au>Weller, Charlotte L.</au><au>Osterholm, Michael T.</au><aucorp>The Coronavirus Vaccines R&D Roadmap Taskforce</aucorp><aucorp>Coronavirus Vaccines R&D Roadmap Taskforce</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2023-03-24</date><risdate>2023</risdate><volume>41</volume><issue>13</issue><spage>2101</spage><epage>2112</epage><pages>2101-2112</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) is aimed at promoting the development of such vaccines. The CVR, funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, was generated through a collaborative and iterative process, which was led by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and involved 50 international subject matter experts and recognized leaders in the field. This report summarizes the major issues and areas of research outlined in the CVR and identifies high-priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 26 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research campaigns that promote the development of broadly protective coronavirus vaccines.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>36870874</pmid><doi>10.1016/j.vaccine.2023.02.032</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2023-03, Vol.41 (13), p.2101-2112 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9941884 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animal models Animals Broadly protective coronavirus vaccines Charities Coronavirus Coronavirus vaccines Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 Vaccines Epidemics finance human diseases Humans Immunology Infectious diseases issues and policy Iterative methods Medical research Middle East respiratory syndrome Minnesota pandemic Pandemic preparedness Pandemics Pandemics - prevention & control Product development Public health R&D Research & development research and development Review Roadmap SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 vaccine development Vaccine research Vaccines Viral diseases virology |
| title | A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T18%3A12%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20research%20and%20development%20(R&D)%20roadmap%20for%20broadly%20protective%20coronavirus%20vaccines:%20A%20pandemic%20preparedness%20strategy&rft.jtitle=Vaccine&rft.au=Moore,%20Kristine%20A.&rft.aucorp=The%20Coronavirus%20Vaccines%20R&D%20Roadmap%20Taskforce&rft.date=2023-03-24&rft.volume=41&rft.issue=13&rft.spage=2101&rft.epage=2112&rft.pages=2101-2112&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2023.02.032&rft_dat=%3Cproquest_pubme%3E2789718511%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2789718511&rft_id=info:pmid/36870874&rft_els_id=S0264410X23001676&rfr_iscdi=true |